and applicable Laws, but shall not include reminder details or e-details, as such terms are generally understood in the pharmaceutical industry in the Territory, or any presentations made at conventions, consulting programs or similar gatherings, other than a pre-arranged or scheduled meeting at such gathering between the sales representative and a Health Care Professional. When used as a verb, "Detail" means to deliver the presentation described in this definition. "Detailing" shall have a corresponding meaning. 1.34 "Detailing Period" means each of the following periods: (a) the period beginning on the Start Date and ending on September 30, 2019; (b) October 1, 2019 through December 31, 2019; and (c) January 1, 2020 through March 31, 2020. 1.35 "Diligent Efforts" means, with respect to an activity to be undertaken by a Party pursuant to this Agreement, the level of efforts and resources normally used by such Party with respect to a pharmaceutical product owned or controlled by such Party, or to which such Party has similar rights, which product is of similar market potential and strategic value and is at a similar stage in its development or life as is the Product, taking into account all relevant factors, including issues of safety, efficacy, product profile, the competitiveness of the marketplace, the proprietary position of the Product, regulatory matters, profitability of the Product and other relevant commercial factors. 1.36 "Disclosing Party" has the meaning set forth in Section 9.1.3. 1.37 "Disputes" has the meaning set forth in Section 13.1. 1.38 "Dual Target" has the meaning set forth in Exhibit B. 1.39 "Effective Date" has the meaning set forth in the preamble to this Agreement. 1.40 "Expiration Date" means March 31, 2020. 1.41 "FDA" means the United States Food and Drug Administration or any successor agency thereto. 1.42 "Fee Notice" has the meaning set